Hemostatic devices and methods of use

Patent metadata

Field	Value
Publication number	US-10933174-B2
Application number	US-201715583124-A
Country	US
Kind code	B2
Filing date	May 1, 2017
Priority date	May 3, 2016
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.

First claim

What is claimed is:

1. An anchorage device configured to surround an implantable medical device, the anchorage device comprising:
a biodegradable substrate made from a first hemostatic agent; and
a second hemostatic agent selectively positioned on the substrate such that the substrate comprises a plurality of first portions that each include the second hemostatic agent and are spaced apart from one another by a second portion of the substrate that does not include the second hemostatic agent.

2. An anchorage device as recited in claim 1 , wherein the second hemostatic agent is selectively positioned on the substrate such that the second hemostatic agent is targeted to a location of blood loss in a patient when the anchorage device is implanted within the patient.

3. An anchorage device as recited in claim 1 , wherein the substrate comprises opposite top and bottom surfaces, the second hemostatic agent being positioned on the bottom surface.

4. An anchorage device as recited in claim 1 , wherein the substrate comprises opposite top and bottom surfaces, the second hemostatic agent being positioned on the bottom surface and is spaced apart from the top surface.

5. An anchorage device as recited in claim 1 , wherein the second hemostatic agent is positioned about a perimeter of the substrate.

6. An anchorage device as recited in claim 1 , wherein the second hemostatic agent is positioned about an entire perimeter of the substrate and is spaced apart from an interior portion of the substrate.

7. An anchorage device as recited in claim 1 , wherein the substrate comprises a first piece and a second piece that is joined with the first piece, the first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity, the implantable medical device being configured to be inserted through the opening and into the cavity.

8. An anchorage device as recited in claim 7 , wherein the second hemostatic agent is selectively positioned on the first piece and an active pharmaceutical ingredient is selectively positioned on the second piece, the second piece being free of the second hemostatic agent.

9. An anchorage device as recited in claim 8 , wherein the active pharmaceutical ingredient is selected from a group consisting of anesthetics, antibiotics, anti-inflammatory agents, procoagulant agents, fibrosis-inhibiting agents, anti-scarring agents, leukotriene inhibitors/antagonists, cell growth inhibitors and mixtures thereof.

10. An anchorage device as recited in claim 8 , wherein the second hemostatic agent is selected from a group consisting of epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose.

11. An anchorage device as recited in claim 7 , wherein the second hemostatic agent is selectively positioned on the first and second pieces and an active pharmaceutical ingredient is selectively positioned on at least one of the first and second pieces.

12. An anchorage device as recited in claim 7 , wherein the first and second pieces each comprise a first portion and a second portion, the second hemostatic agent being selectively positioned on the first portions, an active pharmaceutical ingredient being selectively positioned on the second portions.

13. An anchorage device as recited in claim 1 , wherein:
the first hemostatic agent is collagen; and
the substrate is made entirely from the first hemostatic agent.

14. An anchorage device as recited in claim 7 , wherein the active pharmaceutical ingredient is selected from the group consisting of rifampin and minocycline and mixtures thereof.

15. An anchorage device as recited in claim 1 , further comprising a polymer that is applied to the substrate, the polymer comprising the second hemostatic agent.

16. An anchorage device as recited in claim 15 , wherein the polymer is selected from a group consisting of polylactic acid, polyglycolic acid, poly(L-lactide), poly(D,L-lactide)polyglycolic acid[polyglycolide], poly(L-lactide-co-D,L-lactide), poly(L-lactide-co-glycolide), poly(D, L-lactide-co-glycolide), poly(glycolide-co-trimethylene carbonate), poly(D, L-lactide-co-caprolactone), poly(glycolide-co-caprolactone), polyethylene oxide, polydioxanone, polypropylene fumarate, poly(ethyl glutamate-co-glutamic acid), poly(tert-butyloxy-carbonylmethyl glutamate), polycaprolactone, polycaprolactone co-butylacrylate, polyhydroxybutyrate, copolymers of polyhydroxybutyrate, poly(phosphazene), poly(phosphate ester), poly(amino acid), polydepsipeptides, maleic anhydride copolymers, polyiminocarbonates, poly[(97.5% dimethyl-trimethylene carbonate)-co-(2.5% trimethylene carbonate)], poly(orthoesters), tyrosine-derived polyarylates, tyrosine-derived polycarbonates, tyrosine-derived polyiminocarbonates, tyrosine-derived polyphosphonates, polyethylene oxide, polyethylene glycol, polyalkylene oxides, hydroxypropylmethylcellulose, polysaccharides, hyaluronic acid, chitosan, regenerate cellulose and mixtures thereof.

17. An anchorage device configured to surround an implantable medical device, the anchorage device comprising:
a substrate consisting of a first hemostatic agent, the first hemostatic agent being selected from the group consisting of collagen, epinephrine, tranexamic acid, chitosan and cellulose;
a second hemostatic agent selectively positioned on the substrate such that the substrate comprises a plurality of first portions that each include the second hemostatic agent positioned thereon and are spaced apart from one another by a second portion of the substrate that does not include the second hemostatic agent positioned thereon; and
an active pharmaceutical ingredient selectively positioned on the substrate.

18. An anchorage device as recited in claim 17 , wherein the active pharmaceutical ingredient is selectively positioned on the substrate such that active pharmaceutical ingredient is targeted to a location to treat at least one condition when the anchorage device is implanted within the patient.

19. An anchorage device as recited in claim 17 , wherein the active pharmaceutical ingredient is selectively positioned on the substrate such that active pharmaceutical ingredient is targeted to a location to provide pain relief, inhibit scarring or fibrosis and/or inhibit bacterial growth.

20. An anchorage device configured to surround an implantable medical device, the anchorage device comprising:
a substrate consisting of tranexamic acid; and
rifampin and minocycline selectively positioned on the substrate.

Assignees

• Tyrx Inc
• Medtronic Inc

Inventors

• Pulapura Satish
• Buevich Fatima
• Soskin Jorie S
• Mansfield Franklin R
• Worrell Kai R
• Wood Charlie
• Blanco Jorge Alberto Trevino

Classifications

• A61L31/04

  Macromolecular materials · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title

• A61L31/146

  Porous materials, e.g. foams or sponges · CPC title

• A61L31/10

  Macromolecular materials · CPC title

• A61L2300/214

  Amino acids · CPC title